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Method and results
In these studies, we isolated the gene for G-rich sequence factor 1 (GRSF-1), a cytosolic RNA binding protein which binds to speci®c G-rich sequences found in RNA sequences and is believed to play a role in post-transcriptional control of cellular gene expression.
GRSF-1 mRNA and protein expression was found to be downregulated in prostate cancer cells treated with the differentiation-inducing agents phenylacetate and phenylbutyrate, suggesting that it may be an important marker of prostate carcinogenesis and cancer virulence. GRSF-1 expression was examined in several laboratory models of prostate cancer progression and was signi®-cantly upregulated in association with the acquisition of both the tumourigenic and metastatic phenotype.
Overexpression of GRSF-1, using a sense construct transfected into the prostate cancer cell line LNCaP, resulted in signi®cantly increased soft agar colony formation, which correlates with in vivo tumourigenicity and cancer virulence. Conversely, inhibition of GRSF-1 expression using an antisense construct transfected into a highly tumourigenic and metastatic subline of LNCaP resulted in a signi®cant reduction in soft agar colony formation.
We used the G-rich sequence identi®ed and bound by the GRSF-1 protein to search all published sequences in GenBank for evidence of homology. We detected a variety of genes that contained the G-rich sequence in either the 5 0 -untranslated, 3 0 -untranslated or coding region, including many genes of signi®cant importance in prostate cancer biology. Of particular interest, we noted the presence of the G-rich sequence binding site in the mRNA for prostate-speci®c antigen (PSA) and the proto-oncogene bcl-2.
In our GRSF-1 sense stable transfectants that overexpress GRSF-1, we noted signi®cantly increased expression of bcl-2 protein without alterations in bcl-2 mRNA expression, compared with vector-only transfected controls. This suggests that the GRSF-1 protein may bind to the bcl-2 mRNA and enhance protein translation without altering cellular mRNA levels. We evaluated the expression of GRSF-1 protein in clinical specimens of normal prostate and prostate cancer, using immunohistochemistry. GRSF-1 protein expression was limited to the basal cells of the normal prostate. Increased expression of GRSF-1 protein was associated with the development of prostate intraepithelial neoplasia and prostate cancer.
Conclusion
The intensity and homogeneity of GRSF-1 staining in the prostate cancer specimens signi®cantly correlated with Gleason grade. We also noted signi®cantly increased expression of the GRSF-1 protein in clinical specimens of both nodal and bone metastases. Taken together, these data demonstrate that the RNA binding protein GRSF-1 represents a novel marker of prostate carcinogenesis and cancer progression. The role of post-transcriptional control of gene expression remains poorly understood in the ®eld of prostate cancer. Further studies on the role of GRSF-1 in prostate cancer biology may elucidate the importance of post-transcriptional control of gene expression as a pathway for prostate cancer progression and allow the identi®cation and development of novel therapeutic targets.
